This interactive course provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.
At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Program Coordinator, Oncology Medication Assistance Program
Yale-New Haven Hospital
After completing this activity, the participants should be better able to:
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or ecipant should be better able to:mploying any therapies described in this educational activity.
Continuing Education Information
Credit Available: February 5, 2019 - February 5, 2020
Approximate Time to Complete: 45 minutes
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Transcript information will be sent to the CPE Monitor Service within 4-5 weeks.
(Universal Activity Number - JA4008162-9999-19-605-H04-P)
Type of Activity: Knowledge
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.70 contact hours. There are no pharmacotherapy contact hours for Advanced Practice Registered Nurses.
Charles Lynch - Advisory Board for Genentech and AbbVie, Speakers' Bureau for Genentech
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Directors, Inc.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service, within 4-5 weeks.
Upon completion of this activity, participants will be able to:
Accreditation Council for Pharmacy Education
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.70
No pharmacotherapy hours with this course
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.75
Accreditation Council for Continuing Medical Education (non-MD/DO)
AMA PRA Category 1 Credit(s)™: 0.75
Certificate of Participation (No Credit)
Certificate of Participation: 0.00
2019 Interactive Course: Practical Barriers to Cancer Immunotherapy (Advances in Cancer Immunotherapy)
This activity is presented free of charge.